

Scientific Program

Opening Remarks

Room 1 (Main Room C+D) 10:45-10:55 on October 15 (Friday) 2021
Shuichiro Shiina (Japan)

Closing Remarks

Room 1 (Main Room C+D) 13:00-13:10 on October 17 (Sunday) 2021
Shuichiro Shiina (Japan)

Presidential Lecture

PL

Room 1 (Main Room C+D) 13:00-13:50 on October 16 (Saturday) 2021
Chair: Masao Omata (Japan)

PL-1 : A proposal for Asian Conference on Tumor Ablation guidelines for hepatocellular carcinoma
Shuichiro Shiina (Japan)

Symposium

SY : What is necessary to improve outcomes in ablation?

Room 1 (Main Room C+D) 13:30-17:00 on October 15 (Friday) 2021
Chairs: Shi-Ming Lin (Taiwan), Masao Omata (Japan)

SY-1 : Introductory remark and hepatologist view

Masao Omata (Japan)

SY-2 : Advice from a surgeon: RFA is not an enemy but a surgical ally in the fight against HCC

Norihiro Kokudo (Japan)

SY-3 : What is necessary to improve outcomes in ablation?

Advices from a diagnostic radiological point of view

Yong Moon Shin (Korea)

SY-4 : What is necessary to improve outcomes in ablation? VIR Perspectives

Alex Tang (Malaysia)

SY-5 : Advices from a therapeutic radiological point of view

Masaru Wakatsuki (Japan)

SY-6 : Role of systemic therapy on ablation therapy for HCC

Masatoshi Kudo (Japan)

SY-7 : Pathological findings of locally recurrent HCC after radiofrequency ablation

Yuki Fukumura (Japan)

SY-8 : Recent progress in basic and clinical research of liver cancer stem cells: correlation of liver cancer stem cells with molecular hepatocellular carcinoma subclasses

Taro Yamashita (Japan)

SY-9 : Concluding Remarks:

Shuichiro Shiina (Japan)

Joint Symposium

JS1 : How to apply ultrasound for Ablation

Room 3 (Main Room A) 9:00-10:45 on October 16 (Saturday) 2021
Chair: Hong Soo Kim (Korea), Yasunori Minami (Japan)

JS1-1 : Ultrasound for Ablation by Canon Medical Systems Corporation

Yoshihiko Nomi (Japan)

JS1-2 : Ultrasound for Ablation by GE Healthcare

Yasunori Minami (Japan)

Scientific Program

JS1-3 : Advanced Image Fusion Tools for Tumor Ablation by Philips
Thomas Tang (Canada)

JS1-4 : Tissue Viability Imaging for Ablation by TechsoMed
Yossi Abu (Israel)

JS2 : Current Status and Future Direction of Ablation

Room 1 (Main Room C+D) 14:00-17:10 on October 16 (Saturday) 2021
Chair: Peihong Wu (China), Masatoshi Tanaka (Japan)

JS2-1 : Radiofrequency Ablation by Medtronic
Reto Bale (Austria)

JS2-2 : Radiofrequency Ablation by Japan Lifeline
Haruyuki Takaki (Japan)

JS2-3 : Microwave Ablation by Medtronic
Martijn R. Meijerink (Netherlands)

JS2-4 : Microwave Ablation by Mina-Pro Scientific Inc.
Bo Zhai (China)

JS2-5 : Microwave Ablation by Canyon Medical Inc.
Ping Liang (China)

JS2-6 : Microwave Ablation by Nanjing ECO Microwave System
Ming Zhao (China)

JS2-7 : Irreversible electroporation by Angio Dynamics
Kai-Wen Huang (Taiwan)

JS2-8 : Concluding Remarks:
Shuichiro Shiina (Japan)

Premium Video Session

PVS : “How I do it”

Room 1 (Main Room C+D) 10:10-11:40 on October 16 (Saturday) 2021
Chairs: Kai-Wen Huang (Taiwan), Hideyuki Tamai (Japan)

PVS-1 : How to prevent the biliary tract injury during liver tumor ablation
Xiao-Yan Xie (China)

PVS-2 : Fusion imaging in local ablative therapy for liver cancer
Hidekatsu Kuroda (Japan)

PVS-3 : Artificial ascites: When and how?
Min Woo Lee (Korea)

PVS-4 : Artificial pleural effusion
Ryosuke Tateishi (Japan)

PVS-5 : CT guided ablation
Koichiro Yamakado (Japan)

PVS-6 : Irreversible electroporation of hepatocellular carcinoma: the role of ultrasound
Katsutoshi Sugimoto (Japan)

Keynote Lecture

KL1

Room 2 (Main Room B) 13:30-15:10 on October 15 (Friday) 2021
Chairs: Shu Huei Shen (Taiwan), Miyuki Sone (Japan)

KL1-1 : Radiofrequency ablation or microwave ablation, which is the optimal treatment of patients with early multiple primary lung cancer?
Jianjun Han (China)

Scientific Program

KL1-2 : Ablation of renal cell carcinoma

Koichiro Yamakado (Japan)

KL1-3 : Ablation for bone tumors

Masaya Miyazaki (Japan)

KL1-4 : ACTA guidelines of adrenal tumor ablation

Byung Kwan Park (Korea)

KL2

Room 2 (Main Room B) 9:00-10:15 on October 16 (Saturday) 2021

Chairs: Jen-I Hwang (Taiwan), Nobuyuki Enomoto (Japan)

KL2-1 : PET-CT Guided Liver Ablation: How I Do It

Ramon Sunico Santos-Ocampo (Philippines)

KL2-2 : Hydrodissection during ablative therapy: techniques under CT guidance

Arvind Kumar Chaturvedi (India)

KL2-3 : How to minimize complications in radiofrequency ablation for liver tumor?

Koji Uchino (Japan)

Asian Forum

AF1 : Experience sharing from ACTA cooperative members

Room 3 (Main Room A) 11:20-12:10 on October 15 (Friday) 2021

Chairs: Diana Alcantara Payawal (Philippines), Shuichiro Shiina (Japan)

AF1-1 : Current Circumstance of tumor ablation in Philippines

Ramon Sunico Santos-Ocampo (Philippines)

AF1-2 : Current Circumstance of tumor ablation in Vietnam

Le Van Khang (Vietnam)

AF1-3 : Current Circumstance of tumor ablation in Thailand

Nutcha Pinjaroen (Thailand)

AF1-4 : Current Circumstance of tumor ablation in Cambodia

Chea Chandy (Cambodia)

AF1-5 : Current Circumstance of tumor ablation in Indonesia

Rino Alvani Gani (Indonesia)

AF2 : Experience sharing from ACTA cooperative members

Room 3 (Main Room A) 13:40-14:20 on October 15 (Friday) 2021

Chairs: Uei Pua (Singapore), Ryoosuke Tateishi (Japan)

AF2-1 : Current Circumstance of tumor ablation in Malaysia

Chun Cheng Lee (Malaysia)

AF2-2 : Current Circumstance of tumor ablation in Singapore

Uei Pua (Singapore)

AF2-3 : Current Circumstance of tumor ablation in India

Suyash Sureshchandra Kulakrni (India)

AF2-4 : Current Circumstance of tumor ablation in Bangladesh

Bishwajit Bhowmik (Bangladesh)

AF3 : Experience sharing from ACTA cooperative members

Room 3 (Main Room A) 14:30-15:10 on October 15 (Friday) 2021

Chairs: Amarsausa Jazag (Mongolia), Tatsuya Yamashita (Japan)

AF3-1 : Current Circumstance of tumor ablation in Kazakhstan

Niyaz Malayev (Kazakhstan)

AF3-2 : Current Circumstance of tumor ablation in Russia

Igor Olegovich Rutkin (Russia)

Scientific Program

AF3-3 : Current Circumstance of tumor ablation in Mongolia
Erdenebulgan Batmunkh (Mongolia)

AF4 : Experience sharing from ACTA cooperative members

Room 2 (Main Room B) 16:40-17:20 on October 16 (Saturday) 2021
Chair: Mohammed T. Alshammari (Saudi-Arabia), Yoshinari Asaoka (Japan)

AF4-1 : Current Circumstance of tumor ablation in Ukraine
Sviatoslav Balaka (Ukraine)

AF4-2 : Current Circumstance of tumor ablation in Turkey
Evern Üstüner (Turkey)

AF4-3 : Current Circumstance of tumor ablation in Saudi-Arabia
Bandar Osaid Safar (Saudi-Arabia)

AF4-4 : Current Circumstance of tumor ablation in Israel
Yossi Abu (Israel)

AF5 : Experience sharing from ACTA cooperative members

Room 2 (Main Room B) 10:40-11:40 on October 17 (Sunday) 2021
Chairs: Hyunchul Rhim (Korea) , Kazuhiro Nouse (Japan)

AF5-1 : Current Circumstance of tumor ablation in Japan
Takuma Nakatsuka (Japan)

AF5-2 : Current Circumstance of tumor ablation in Taiwan
Sheng-Nan Lu (Taiwan)

AF5-3 : Current Circumstance of tumor ablation in Korea
Young Joon Lee (Korea)

AF5-4 : Current Circumstance of tumor ablation in China
Pei-Hong WU (China)

AF5-5 : Current Circumstance of tumor ablation in Hong Kong
Danny Hing Yan Cho (Hong Kong)

AF5-6 : Current Circumstance of tumor ablation in Australia
Nick Brown (Australia)

AF6 : Asian Forum Manufacture Session

Room 4 (Seminar Room D) 9:00-10:00 on October 16 (Saturday) 2021
Chairs: Shi-Ming Lin (Taiwan), Naoya Sakamoto (Japan)

AF6-1 : Current Circumstance of tumor ablation by Japan Lifeline

AF6-2 : Current Circumstance of tumor ablation by Boston Scientific

AF6-3 : Current Circumstance of tumor ablation by Nanjing ECO Microwave System

AF6-4 : Current Circumstance of tumor ablation by STARmed

AF6-5 : Current Circumstance of tumor ablation by Mina-Pro Scientific Inc.

Cutting-edge Seminar

CS : Ablation of Thyroid Tumor

Room 2 (Main Room B) 14:00-15:15 on October 16 (Saturday) 2021
Chair: Hitoshi Noguchi (Japan)

CS-1 : Current status and future prospects of therapeutic thyroid Intervention in Japan
Nobuhiro Fukunari (Japan)

Scientific Program

CS-2 : Radiofrequency ablation of primary thyroid microcarcinoma
Jung Hwan Baek (Korea)

CS-3 : Clinical implication of Radiofrequency ablation in locally recurrent thyroid cancer
Wei-Che Lin (Taiwan)

Focus Session

FS1 : Aging Society and Ablation: Up to What Age Can We Consider Performing Ablation?

Room 2 (Main Room B) 11:00-11:45 on October 15 (Friday) 2021

Chairs: Sheng-Nan Lu (Taiwan) , Yoichi Hiasa (Japan)

FS1-1 : Ablation of liver cancer in patients aged more than 80 years
Masashi Hirooka (Japan)

FS1-2 : Cause-specific mortality associated with aging in HCC patients treated with radiofrequency ablation
Naoto Fujiwara (Japan)

FS1-3 : Aging society and ablation: up to what age can we consider performing ablation?
Atushi Hiraoka (Japan)

FS2 : Vascular Intervention and Ablation

Room 3 (Main Room A) 16:10-16:55 on October 15 (Friday) 2021

Chairs: Alex Tang (Malaysia), Hiroaki Nagamatsu (Japan)

FS2-1 : Vascular intervention and ablation
Peter Yu-Tang Goh (Singapore)

FS2-2 : Hepatic Artery Infusion Chemotherapy Combined with Apatinib and Camrelizumab for Hepatocellular Carcinoma (HCC) in BCLC C stage: a prospective, single-arm, phase II trial
Yangkui Gu (China)

FS2-3 : Ablation therapy could be selected after multidisciplinary treatment including Ultra-FP or DEB-TACE+B-TACE among the BCLC B-D HCC patients
Yasuteru Kondo (Japan)

FS3 : What is cryoablation?

Room 2 (Main Room B) 15:15-16:15 on October 16 (Saturday) 2021

Chairs: Lizhi Niu (China), Shunsuke Sugawara (Japan)

FS3-1 : Computed tomography-guided percutaneous cryoablation for lung ground-glass opacity: A pilot study
Lizhi Niu (China)

FS3-2 : Is cryoablation for RCC safe?
Toshihiro Iguchi (Japan)

FS3-3 : Cryoablation for the treatment of oligometastatic disease to the lung
Thierry de Baere (France)

FS3-4 : Nonsurgical Cryoablation for small breast cancer-14-year result
Eisuke Fukuma (Japan)

FS4 : Cost-Effectiveness of Ablation

Room 2 (Main Room B) 9:00-9:45 on October 17 (Sunday) 2021

Chairs: Roy Joseph Santosham (India), Kiyoshi Hasegawa (Japan)

FS4-1 : Cost-effectiveness of hepatic resection and radiofrequency ablation for initial treatment of hepatocellular carcinoma: a Markov Model Analysis
Masaya Sato (Japan)

FS4-2 : Cost effectiveness of Ablation
Lijesh Kumar (India)

Scientific Program

FS4-3 : TBA

Suyash Kulkarni (India)

FS5 : Education in Ablation

Room 2 (Main Room B) 9:45-10:30 on October 17 (Sunday) 2021

Chairs: Wei-Ting Chen (Taiwan), Shuji Terai (Japan)

FS5-1 : About Japan ablation webinar and international ablation webinar

Maki Tobari (Japan)

FS5-2 : Pretreatment planning with Real-time Virtual Sonography before percutaneous ablation for hepatocellular carcinoma

Sawako Uchida-Kobayashi (Japan)

FS5-3 : Importance of training in percutaneous ablation for hepatocellular carcinoma

Yasuyuki Komiyama (Japan)

Intensive Session

IS1 : Ablation of Hepatocellular Carcinoma

Room 1 (Main Room C+D) 10:00-10:40 on October 15 (Friday) 2021

Chairs: Bo Zhai (China), Akio Saiura (Japan)

IS1-1 : Survival impact of hepatitis C virus elimination in hepatocellular carcinoma after curative treatment

Naoto Fujita (Japan)

IS1-2 : Initial experience using emprint ablation system for hepatocellular carcinoma

Nobuhito Taniki (Japan)

IS1-3 : Therapeutic effects and complications of microwave ablation for hepatocellular carcinoma

Shinichiro Nakamura (Japan)

IS2 : Cryoablation

Room 2 (Main Room B) 15:30-16:30 on October 15 (Friday) 2021

Chairs: Byung Kwan Park (Korea), Yusuke Matsui (Japan)

IS2-1 : Combination of cryoablation and radiofrequency ablation to treat T1a and T1b renal cell carcinomas

Byung Kwan Park (Korea)

IS2-2 : Ureteral displacement by pushing guidewire-technique with antegrade pyeloperfusion for ensuring the ureteral thermoprotection during cryoablation of medial/inferior renal tumors

Chihiro Itou (Japan)

IS2-3 : The clinical effectiveness of cryoablation for T1b renal cell carcinoma and combination therapy of transcatheter arterial embolization; propensity score matched analysis

Yuichi Sugino (Japan)

IS2-4 : Percutaneous ablation of renal masses - an educational exhibit

Rishabh Jain (India)

IS2-5 : Reversible Electrochemotherapy (ECT) as a Treatment Option for Local RCC Recurrence in Solitary Kidney

Flavio Andresiani (Italy)

IS3 : Ablation of Colorectal Liver Metastasis

Room 1 (Main Room C+D) 9:00-10:00 on October 16 (Saturday) 2021

Chairs: Hsin-yi Chen (Taiwan), Toru Beppu (Japan)

IS3-1 : Thermal ablation in the multidisciplinary treatment for patients with initially unresectable colorectal liver metastases

Toru Beppu (Japan)

Scientific Program

IS3-2 : Strategy and the results of liver metastasis from colorectal cancer

-The consideration of the local recurrence after the ablation for CRLM-

Yuko Takami (Japan)

IS3-3 : Evaluation of radiofrequency ablation therapy of liver metastases from colorectal cancer

Kazuharu Suzuki (Japan)

IS3-4 : The effectiveness of radio-frequency ablation as a treatment for metastatic liver tumors: interim analysis of single-arm prospective study

Takamasa Ohki (Japan)

IS3-5 : Depiction of tumor margins on the early follow-up unenhanced MRI after ablation therapies for hepatocellular carcinoma

Yun Ku Cho (Korea)

IS3-6 : Multidisciplinary predictive model for recurrence and survival after radiofrequency ablation for hepatocellular carcinoma

Dong Ik Cha (Korea)

IS4 : Pharmacological therapy and ablation

Room 1 (Main Room C+D) 9:00-10:00 on October 17 (Sunday) 2021

Chairs: I-Cheng Lee (Taiwan), Haruyuki Takaki (Japan)

IS4-1 : Ablation and immunomodulation

Haruyuki Takaki (Japan)

IS4-2 : Expanding indication of radiofrequency ablation by molecular target agents

Kazuhiro Nouse (Japan)

IS4-3 : Radiofrequency ablation therapy (RFA) for molecular targeted agent (MTA) unsuccessful cases in Hepatocellular carcinoma(HCC) patients

Takuma Kaneko (Japan)

IS4-4 : Safe radiofrequency ablation for low platelet count patients with novel platelet count raising drug (Lusutrombopag)

Hideo Yoshida (Japan)

IS4-5 : Peptide-loaded dendritic cell vaccine enhances tumor-specific immune responses after radiofrequency ablation therapy for hepatocellular carcinoma

Hidetoshi Nakagawa (Japan)

IS4-6 : Combination of ablation and systemic therapy for the management of liver cancer

I-Cheng Lee (Taiwan)

ACTA Meets SIO (Society of Interventional Oncology)/ CIRSE (Cardiovascular and Interventional Radiological Society of Europe)

AMS

Room 1 (Main Room C+D) 11:00-12:30 on October 15 (Friday) 2021

Chairs: Uei Pua (Singapore), Koichiro Yamakado (Japan)

AMS-1 : Ablation and fixation tumors in the bony pelvis

Jack William Jennings (USA)

AMS-2 : Ablation in the peripheral musculoskeletal system

Dimitrios Filippiadis (Greece)

AMS-3 : Ablation and consolidation in malignant spine disease, why and how

Alexis Kelekis (Greece)

Oral

Oral 1 : Ablation and TACE/radiation/chemotherapy

Room 2 (Main Room B) 9:30-10:40 on October 15 (Friday) 2021

Chairs : Polin Tseng (Taiwan), Hayato Nakagawa (Japan)

01-1 : Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma

Kei Endo (Japan)

01-2 : Clinical outcomes of radiofrequency ablation combined with trans-arterial embolization using degradable starch microsphere for the treatment of liver tumors other than hepatocellular carcinoma

Takaaki Hasegawa (Japan)

01-3 : Analysis of factors related to TACE eligibility in patient with intermediate stage hepatocellular carcinoma

Ryosuke Kasuga (Japan)

01-4 : Stereotactic body radiation therapy as a salvage treatment for percutaneous ablation of hepatocellular carcinoma

Koshiro Fukuda (Japan)

01-5 : A long surviving patient despite having multiple HCCs, who is treated by radiofrequency ablation on the basis of low and long term doses of sorafenib

Keisuke Hamamura (Japan)

01-6 : Combination of the oncolytic immunotherapy ONCORINE with the PD-1 Receptor blocking antibody nivolumab in patients with advanced HCC who have failed prior systemic therapy

Jing Xie (China)

01-7 : Steroid administration for ischemic complication after radiofrequency ablation

Taijiro Wake (Japan)

Oral 2 : RFA for difficult cases

Room 3 (Main Room A) 9:30-10:20 on October 15 (Friday) 2021

Chairs : Ming Feng Chiang (Taiwan), Teiji Kuzuya (Japan)

02-1 : Efficacy of radiofrequency ablation for focal hepatic lesions adjacent to gallbladder

Batmunkh Erdenebulgan (Mongolia)

02-2 : Tumor close to the gallbladder: Let us freeze it!

Prabhjot Singh Chowhan (India)

02-3 : Focal hydrodissection for ablation of the tumor that abutting gallbladder; A case series

Ching Charoenvisal (Thailand)

02-4 : Radiofrequency ablation therapy for super-old patients with hepatocellular carcinoma over 85 years old

Kuniaki Arai (Japan)

02-5 : The safety and efficacy of combination therapy of PEIT and RFA for difficult-to-treat HCCs

Sena Higashi (Japan)

Oral 3 : Lung

Room 2 (Main Room B) 10:30-11:50 on October 16 (Saturday) 2021

Chairs : Jiachang Chi (China), Atsuhiko Nakatsuka (Japan)

03-1 : Clinical outcomes and techniques for radiofrequency ablation of lung tumors smaller than 1 cm

Takaaki Hasegawa (Japan)

03-2 : CT-guided microwave ablation of pulmonary ground-glass opacity nodules located in risk areas: Preliminary results

Jiachang Chi (China)

03-3 : CT-guided microwave ablation of peripheral lung malignancy: effect of subpleural multisite anesthesia for pain relief

Jiachang Chi (China)

Scientific Program

03-4 : Computed tomography-guided percutaneous cryoablation for lung ground-glass opacity: A pilot study

Lizhi Niu (China)

03-5 : A case of hemostasis by CT-guided RFA for massive hemothorax due to ruptured chest wall metastasis of renal cell carcinoma

Noriaki Yuasa (Japan)

03-6 : Preliminary clinical application of multimodal microwave ablation in the treatment of lung carcinoma based on CT and MR imaging

Xiao Kang Shen (China)

03-7 : Clinical outcomes of hybrid treatment of surgery and radiofrequency ablation for multiple lung metastases

Takaaki Hasegawa (Japan)

03-8 : Risk factor of local tumor progression after radiofrequency ablation for lung metastases from colorectal carcinoma: Supplementary analysis of phase II trial (MLCSG-0802)

Takaaki Hasegawa (Japan)

Oral 4 : MWA

Room 3 (Main Room A) 10:40-11:50 on October 16 (Saturday) 2021

Chairs : David Yurui Lim (Singapore), Nobuhito Taniki (Japan)

04-1 : Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma

Sawako Uchida-Kobayashi (Japan)

04-2 : A novel hemostasis technique of needle tract bleeding after microwave ablation for hepatic malignant tumors

Takeshi Hatanaka (Japan)

04-3 : New next-generation microwave thermosphere ablation for small hepatocellular carcinoma

Jumpei Okamura (Japan)

04-4 : The efficacy of microwave ablation using thermosphere™ technology versus radiofrequency ablation in the treatment of hepatocellular carcinoma

Tamami Abe (Japan)

04-5 : Utility of additional microwave ablation in patients with hepatocellular carcinoma who received transcatheter arterial chemoembolization

Masahiko Sue (Japan)

04-6 : Treatment outcome of RFA/MWA for hepatocellular carcinoma at high-risk of local/subsegmental recurrence

Shunichi Hosoda (Japan)

04-7 : Comparison of clinical outcomes of microwave ablation therapy with radiofrequency ablation for intermediate hepatocellular carcinoma

Diana Alcantara Payawal (Philippines)

Oral 5 : New techniques

Room 3 (Main Room A) 14:00-14:50 on October 16 (Saturday) 2021

Chairs : Naveen Kalra (India), Kazuyoshi Ohkawa (Japan)

05-1 : Evaluation of coagulated area in HCC patients performed by RFA using “arfa”

Yohei Miyachi (Japan)

05-2 : Multiple bipolar radiofrequency ablation in treatment of medium to large hepatomas: Experience in a regional hospital

Po-Jen Hsieh (Taiwan)

05-3 : Safety and efficacy of percutaneous radiofrequency ablation for small juxtacardiac liver tumor by using expandable multitined electrode

Chinnapat Laohachanvanich (Thailand)

Scientific Program

05-4 : Evaluation of new RFA protocol (10W increase per minute) for the treatment of HCC
Miwa Hashizume (Japan)

05-5 : Making the tumour cells porous: Irreversible electroporation of liver cancer
Abhiman S Baloji (India)

Oral 6 : Long-term outcomes of ablation with/without other treatment

Room 3 (Main Room A) 15:10-16:10 on October 16 (Saturday) 2021

Chairs : Wei-Tin Chen (Taiwan), Hironao Okubo (Japan)

06-1 : Therapeutic outcomes of over 3cm or up to 3 hepatocellular carcinomas treated with local ablation
Masashi Ninomiya (Japan)

06-2 : Long-term prognosis of very-early-stage HCC after RFA
Kenta Takaura (Japan)

06-3 : Survival benefits of direct-acting antivirals in patients with HCV-related hepatocellular carcinoma undergoing radiofrequency ablation
I-Cheng Lee (Taiwan)

06-4 : Recurrences are suppressed by elimination of hepatitis C virus using DAA after radical HCC treatment
Ryoko Kuromatsu (Japan)

06-5 : Usefulness of modified albumin-bilirubin TMN (mALBI-T) score as a novel prognostic scoring system of radiofrequency ablation against hepatocellular carcinoma
Atsushi Hiraoka (Japan)

06-6 : Usefulness of shear wave elastography for evaluation of hepatocellular carcinoma recurrence after ablation therapy
Hironori Tanaka (Japan)

Oral 7 : Thyroid

Room 3 (Main Room A) 16:20-17:30 on October 16 (Saturday) 2021

Chairs : My Thi Le (Vietnam), Masahide Nakano (Japan)

07-1 : Principle of Radiofrequency and head and neck applications
Neha Shah (India)

07-2 : Differences in the ultrasonographic appearance of thyroid nodules after radio-frequency ablation
Ming-Hsun Wu (Taiwan)

07-3 : 700 plus benign thyroid nodules with radiofrequency ablation in 4 years: result of 5 medical centers in Taiwan
Cheng-Kang Wang (Taiwan)

07-4 : Residual, regrowth and recurrence of radiofrequency ablation of benign thyroid nodules with different volumes: Two-year results
Hsiu-Ling Chen (Taiwan)

07-5 : Efficacy and safety of single session radiofrequency ablation in treating benign thyroid nodules: a short-term prospective cohort study
Bang Van Nguyen (Vietnam)

07-6 : Clinical evaluation of thyroid RFA for autonomously functioning thyroid nodules in Japan
Masahide Nakano (Japan)

07-7 : Efficiency and safety of radiofrequency ablation for primary and secondary hyperparathyroidism with or without previous parathyroidectomy: a retrospective study
Chi-Cheng Chen (Taiwan)

Scientific Program

Oral 8 : Thyroid and Kidney

Room 4 (Seminar Room D) 10:30-11:50 on October 16 (Saturday) 2021

Chairs : Kuang Hsin Huang (Shingapore), Shigeyoshi Soga (Japan)

08-1 : Clinical indications and evaluation of Thyroid RFA for primary and recurrent thyroid malignancies
Nobuhiro Fukunari (Japan)

08-2 : One year follow-up of US-guided radiofrequency ablation for low-risk papillary thyroid microcarcinoma
Lay San Lim (Taiwan)

08-3 : The importance of nodule size in the management of ruptured thyroid nodule after radiofrequency ablation: a retrospective study and literature review
Wen Chieh Chen (Taiwan)

08-4 : Efficacy and safety of single-session radiofrequency ablation for Intrathoracic goiter
Pi-Ling Chiang (Taiwan)

08-5 : The influence of trans-arterial lipiodol embolization on temperature change during percutaneous cryoablation for renal cell carcinoma
Nai-Wen Chang (Taiwan)

08-6 : A case of Xp11.2 translocation renal cell carcinoma (T3bN0M1) treated with cryoablation after downstaging with immune checkpoint inhibitor
Koji Tomita (Japan)

08-7 : Pneumodissection for urinary tract protection during the percutaneous cryoablation for renal cell carcinoma
Yohei Munetomo (Japan)

08-8 : Uncooled Microwave Ablation of Benign Thyroid Nodules: Long- Term Efficacy, Effects on Thyroid Functions
Gulsah Yildirim (Tarkey)

Oral 9 : Basic and education in ablation

Room 1 (Main Room C+D) 10:10-11:00 on October 17 (Sunday) 2021

Chairs : Shih-Chi Ho (Taiwan), Soo Ryang Kim (Japan)

09-1 : Direction of tissue contraction after microwave ablation: A comparative experimental study in Ex vivo Bovine Liver
Junhyok Lee (Korea)

09-2 : Survival of hepatocellular carcinoma (HCC) patients treated by radiofrequency ablation (RFA): 36 months follow up study
Andri Sanityoso Sulaiman (Indonesia)

09-3 : Parametric studies on temperature-dependent thermomechanical behaviour of soft tissue during ablation treatment
Remi Jacob Lay (Australia)

09-4 : Retrospective study for local tumor progression rate for microwave ablation and multipolar radiofrequency ablation in our department
Ryo Shimizu (Japan)

09-5 : Transarterial embolization using Microspheres combined with Ultrasound-guided Ablation for hepatocellular carcinoma
Wei-Yu Kao (Taiwan)

Oral 10 : Others

Room 1 (Main Room C+D) 11:10-12:00 on October 17 (Sunday) 2021

Chairs : Zafer Unsal Coskun (Turkey), Nutch Pinjaroen (Thailand)

010-1 : Percutaneous cryoablation for the treatment of bone and soft tissue tumors: Initial experience
Junichi Taniguchi (Japan)

Scientific Program

010-2 : Moving-shot technique of radiofrequency ablation for the treatment of symptomatic peripheral vascular malformations

Zafer Unsal Coskun (Turkey)

010-3 : Results of radiofrequency ablation treatment of superficial venous insufficiency of the lower extremities

Baasanjav Narangerel (Mongolia)

010-4 : Study of the effectiveness of radiofrequency ablation treatment in uterine leiomyoma

Gantulga Vanchinsuren (Mongolia)

010-5 : Role of ablation in solitary distant lymph nodal metastases in patients with heavily treated carcinoma gall bladder

Abhishek Bansal (India)

Oral 11 : Technical support for ablation

Room 3 (Main Room A) 9:30-10:20 on October 17 (Sunday) 2021

Chairs : Po-Heng Chuang (Taiwan), Jun Imamura (Japan)

011-1 : Can the entire ablative hyperechoic zone be regarded as a necrotic lesion after radiofrequency ablation of the liver?

Yasunori Minami (Japan)

011-2 : Characteristics of tumor blood flow drainage area (TDA) and therapeutic efficacy of complete TDA ablation in small hepatocellular carcinoma of ≤ 3 cm

Kazuyoshi Ohkawa (Japan)

011-3 : Radiofrequency ablation covering the entire tumor blood drainage area improves recurrences and survival in hepatocellular carcinoma

Masashi Hirooka (Japan)

011-4 : Usefulness of the virtual needle tracking system in RFA

Teiji Kuzuya (Japan)

011-5 : 4D Ultrasonography for therapeutic radiofrequency ablation for hepatocellular carcinoma-included enhanced-ultrasonography-

Naoki Hotta (Japan)

Oral 12 : Surgical resection and metastasis

Room 3 (Main Room A) 10:30-11:40 on October 17 (Sunday) 2021

Chairs : Ngo Le Lam (Vietnam), Tsukasa Aihara (Japan)

012-1 : Comparison of surgical resection and radiofrequency ablation for patients with small hepatocellular carcinoma

Noboru Takata (Japan)

012-2 : Comparison between the efficacy of radiofrequency ablation and liver resection in treating hepatocellular carcinoma

Rino Alvani Gani (Indonesia)

012-3 : Laparoscopic radiofrequency ablation versus percutaneous radiofrequency ablation for subphrenic hepatocellular carcinoma

Min Hwan Kwak (Korea)

012-4 : Risk of infectious complication after percutaneous ablation therapy for liver metastasis with a history of biliary reconstruction

Tsukasa Aihara (Japan)

012-5 : Percutaneous radiofrequency ablation (RFA) for patients with unresectable colorectal cancer liver metastases

Toshihiko Ohnishi (Japan)

012-6 : The latest procedure of liver biopsy in the era of cancer genomic Therapies; the single center retrospective analysis

Naoya Kanogawa (Japan)

Scientific Program

012-7 : Significance of radiofrequency ablation for unresectable colorectal cancer with liver metastases
Tomoya Tago (Japan)

Oral 13 : Hydrodissection and complications

Room 4 (Seminar Room C+D) 9:30-10:40 on October 17 (Sunday) 2021
Chairs : Hung-Chuen Chang (Taiwan), Yoshiyuki Ueno (Japan)

013-1 : Artificial ascites in radiofrequency ablation

Rino Alvani Gani (Indonesia)

013-2 : Hydrodissection of the bare area of the liver, can it be done?

David Yurui Lim (Singapore)

013-3 : Radiofrequency ablation for hepatocellular carcinoma with artificial pleural effusion

Nobuo Waguri (Japan)

013-4 : Infectious complications related to radiofrequency ablation of liver tumors: the role of antibiotics

Ryo Nakagomi (Japan)

013-5 : Biliary complication and efficacy after ablation of peribiliary tumor using irreversible electroporation (IRE) versus radiofrequency ablation (RFA)

Rujira Patanawanitkul (Thailand)

013-6 : Complications of radiofrequency ablation: Risk factors and countermeasures

Taijiro Wake (Japan)

013-7 : Safety comparison of overnight admission and 4-hours bedrest after liver microwave ablation

Merve Ozen (United States)

Mini Oral

Mini Oral 1 : Ablation for difficult cases

Room 4 (Seminar Room D) 14:00-15:10 on October 16 (Saturday) 2021
Chairs : Kai Li (China), Takeshi Hatanaka (Japan)

MO1-1 : Two cases of local ablation for hepatocellular carcinoma in the caudate lobe; an emerging technique with using guided needle under computed tomography

Sae Yumita (Japan)

MO1-2 : A case of ablation of HCC bordering the Gleason sheath in hepatic hilar area

Kazuharu Suzuki (Japan)

MO1-3 : Transverse colon perforation after radiofrequency ablation (RFA) procedure for hepatocellular carcinoma in segment 6: A case report

Hideo Yoshida (Japan)

MO1-4 : An experience of radiofrequency ablation for hepatocellular carcinoma adjacent to the left hepatic bile duct by using the latest ablation system "arfa"

Miyuki Nakagawa (Japan)

MO1-5 : A case of radiofrequency ablation for mixed liver cancer in a patient with spina bifida and pelvic ectopia of the liver

Yuko Hijioka (Japan)

MO1-6 : 2 Cases who underwent laparoscopic radiofrequency ablation for hepatocellular carcinoma that was difficult to visualize with abdominal US

Masanori Kawaguchi (Japan)

MO1-7 : Recurrent hepatocellular carcinoma with bile duct invasion mimicking choledocholithiasis after perivascular radiofrequency ablation

Hsin-Yi Chen (Taiwan)

MO1-8 : Two cases of Hepatocellular carcinoma performed ethanol injection

Takuto Yoshioka (Japan)

MO1-9 : Microwave ablation as an adjunct to surgical removal of a rectal cancer metastasis makes an unresectable tumor resectable

Evren Üstüner (Turkey)

Scientific Program

Mini Oral 2 : Ablation with additional support

Room 4 (Seminar Room D) 15:10-16:20 on October 16 (Saturday) 2021

Chairs : Shih-Jer Hsu (Taiwan), Ryota Masuzaki (Japan)

- M02-1 : Radiofrequency ablation as a tool for conversion therapy in patients with advanced hepatocellular carcinoma treated with molecular target agents
Shiho Murakami (Japan)
- M02-2 : Two cases of multiple hepatocellular carcinoma treated with radiofrequency ablation in combination with tyrosine kinase inhibitor
Keita Maki (Japan)
- M02-3 : Cryoablation for tumor with IVC invasion assisted by intravascular balloon occlusion: A case report
Jia-An Hong (Taiwan)
- M02-4 : An older patient with a hepatocellular carcinoma treated via repeated combination trans-arterial chemoembolization and microwave ablation
Masataka Seike (Japan)
- M02-5 : Loco-regional therapy combination transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) in intermediate stage hepatocellular carcinoma (BCLC B) with etiology of fatty Liver-cirrhotic
Fardah Akil (Indonesia)
- M02-6 : Arc ablation needle for treatment of hepatocellular carcinoma with an adherent important structure
Xi xi Sun (China)
- M02-7 : Significance of surveillance in the pelvic cavity after radiofrequency ablation for hepatocellular carcinoma
Yoshihisa Arao (Japan)
- M02-8 : Radiation exposure dose measurement for CT guide radiofrequency ablation of HCC in liver
Yong Moon Shin (Korea)
- M02-9 : Use of PET-MRI in detection of residual or recurrent disease post microwave ablation
Evren Üstüner (Turkey)

Mini Oral 3 : HCC today

Room 4 (Seminar Room D) 16:20-17:30 on October 16 (Saturday) 2021

Chairs : Hong Soo Kim (Korea), Hideo Yoshida (Japan)

- M03-1 : Observation of hepatocellular carcinoma (HCC) in a tertiary center in indonesia: A preliminary report
Eka Surya Nugraha (Indonesia)
- M03-2 : Time trend of local ablation therapy for early stage of hepatocellular carcinoma in Taiwan
Hung-Chuen Chang (Taiwan)
- M03-3 : Frequency of the abrasion therapy in a single central medical institution associates with the future regional mortality of hepatocellular carcinoma
Takuya Kuwashiro (Japan)
- M03-4 : Nomograms based on the tumor location to access the outcomes of radiofrequency ablation for early hepatocellular carcinoma
Chih-Horng Wu (Taiwan)
- M03-5 : Comparison of ease of handling on the local ablation therapy devices based on medical engineer questionnaire
Tomoaki Nagasawa (Japan)
- M03-6 : Serum golgi protein 73 in hepatocellular carcinoma patients
Gontar Alamsyah Siregar (Indonesia)
- M03-7 : The role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with hepatocellular carcinoma: A real-world data analysis
Yohei Koizumi (Japan)

Scientific Program

M03-8 : Treatment of hepatocellular carcinoma in the pandemic of COVID-19

Maki Tobari (Japan)

M03-9 : Albumin-bilirubin grade as a marker of recurrence to difficult-to-cure stages after radiofrequency ablation for hepatocellular carcinoma

Takatoshi Nawa (Japan)

M03-10 : Efficacy of percutaneous radiofrequency ablation as an initial treatment for hepatocellular carcinoma in extremely old-age patients by propensity score matching analyses

Takamasa Ohki (Japan)

Mini Oral 4 : Ablation for specific cases

Room 4 (Seminar Room D) 10:50-11:50 on October 17 (Sunday) 2021

Chairs : Juferdy Kurniawan (Indonesia), Yoshinari Asaoka (Japan)

M04-1 : Two cases of RFA for HCC with Denver shunts

Yuu Shimosuma (Japan)

M04-2 : Two HCC cases treated by TACE and RFA after TIPS for advanced cirrhosis with refractory ascites

Yoshinari Asaoka (Japan)

M04-3 : Takotsubo cardiomyopathy after microwave ablation therapy for hepatocellular carcinoma: A case report

Terunao Iwanaga (Japan)

M04-4 : Radiofrequency ablation for liver metastasis of cervical cancer in a patient with primary biliary cholangitis

Ken Nogami (Japan)

M04-5 : A case of ovarian cancer with complete response to chemotherapy and radiofrequency ablation for liver metastasis

Manabu Hayashi (Japan)

M04-6 : A case of thorotrast intrahepatic cholangiocarcinoma controlled by radiofrequency ablation therapy

Nobuhito Taniki (Japan)

M04-7 : A case of liver tumor in an 8-year-old girl with Li-Fraumeni syndrome who underwent radiofrequency ablation.

Maki Tobari (Japan)

M04-8 : Twice pneumothoraces due to radiofrequency ablation for hepatocellular carcinoma in a patient with interstitial pneumonia: A case report

Chihiro Shiomi (Japan)

Scientific Program

Ablation Webinar Case Study Session

Room 2 (Main Room B) 18:00-18:30 on October 16 (Saturday) 2021

Chairs: David Yurai Lim (Singapore), Hitoshi Maruyama (Japan)

AWC-1 : A case of radiofrequency ablation for recurrent hepatocellular carcinoma located near the gall bladder

Shun-ichi Wakabayashi (Japan)

Late Breaking Session

Room 3 (Main Room A) 15:20-16:00 on October 15 (Friday) 2021

Chairs : Keisuke Hamamura (Japan)

LB-1 : Comparison between Stereotactic Body Radiotherapy and Radiofrequency Ablation as First Therapy for Small Hepatocellular Carcinoma

Baek Gyu Jun (Korea)

LB-2 : Radiofrequency ablation of minimal liver metastasis guided by infusion image of Kupffer cell uptake contrast enhanced ultrasound and MRI

Jingyong Xu (China)

LB-3 : Diaphragm hernia with bowel incarcerated after repeated radiofrequency ablation to HCCs

Po-Heng Chuang (Taiwan)

LB-4 : Long-term outcomes of percutaneous radiofrequency ablation for treatment-naïve hepatocellular carcinoma in Milan criteria: 20 years of single-center experience

Se Young Jang (Korea)

Scientific Program

Morning Seminar

MS1

Sponsored by Eli Lilly Japan K.K.

Room 1 (Main Room C+D) 8:00-9:00 on October 16 (Saturday) 2021

Chair: Katsutoshi Sugimoto (Japan)

MS1-1 : Utility of non-invasive prediction of tumor differentiation in various treatments of hepatocellular carcinoma

Yusuke Kawamura (Japan)

MS1-2 : The impact of multi-molecular targeted agents on the clinical outcomes of unresectable hepatocellular carcinoma in clinical practice: a single-institution study

Tomokazu Kawaoka (Japan)

MS2

Sponsored by Eisai Co., Ltd

Room 2 (Main Room B) 8:00-9:00 on October 16 (Saturday) 2021

Chair: Shuichiro Shiina (Japan)

MS2-1 : Combination strategy with chemotherapy (focused on lenvatinib) and tumor ablation

Takamasa Ohki (Japan)

MS2-2 : Combination therapy with Lenvatinib and RFA

Kazushi Numata (Japan)

MS3

Sponsored by Japan Lifeline Co., Ltd.

Room 1 (Main Room C+D) 8:00-9:00 on October 17 (Sunday) 2021

Chair: Masatoshi Tanaka (Japan)

MS3-1 : The role of Ablative treatment following TACE/HAIC treatment in the era of MTA and iCIs

Yasuteru Kondo (Japan)

MS4

Sponsored by Chugai Pharmaceutical Co.,Ltd.

Room 2 (Main Room B) 8:00-9:00 on October 17 (Sunday) 2021

Chair: Shuichiro Shiina (Japan)

MS4-1 : Real-world experience of atezolizumab plus bevacizumab in Japanese patients with unresectable hepatocellular carcinoma

Namiki Izumi (Japan)

Luncheon Seminar

LS1

Sponsored by Mima-Pro Scientific Inc.

Room 1 (Main Room C+D) 12:30-13:30 on October 15 (Friday) 2021

Chair: Weijun Fan (China)

LS1-1 : Immunomodulatory Effect and Clinical Value of Tumor Ablation

Zhiqiang Meng (China)

LS1-2 : Pathologic Diagnosis and Genetic Analysis of Sequential Biopsy Following Coaxial Low-Power Microwave Thermal Coagulation For Pulmonary Ground-Glass Opacity Nodules

Jiachang Chi (China)

LS2

Sponsored by Bayer Yakuhin, Ltd.

Room 2 (Main Room B) 12:30-13:30 on October 15 (Friday) 2021

Chair: Namiki Izumi (Japan)

LS2-1 : Radiofrequency Ablation for Hepatocellular Carcinoma: The Role of Gadoteric MRI

Ryosuke Tateishi (Japan)

Scientific Program

LS3

Sponsored by Shionogi & Co., Ltd.

Room 1 (Main Room C+D) 12:00-13:00 on October 16 (Saturday) 2021

Chair: Shuichiro Shiina (Japan)

LS3-1 : Toward safe and effective ablation: Experience in 20 years

Ryosuke Tateishi (Japan)

LS4

Sponsored by MIYARISAN PHARMACEUTICAL CO., LTD.

Room 2 (Main Room B) 12:00-13:00 on October 16 (Saturday) 2021

Chair: Nobuhiro Nakamoto (Japan)

LS4-1 : Advances in new microwave ablation therapy and immunotherapy for hepatocellular carcinoma

Nobuhito Taniki (Japan)

LS5

Sponsored by Medtronic

Room 1 (Main Room C+D) 12:00-13:00 on October 17 (Sunday) 2021

Chair: Meng Zhiqiang (China)

LS5-1 : Tumor ablation for metastatic liver tumors: its indication and outcomes

Takamasa Ohki (Japan)

LS5-2 : China Experience of Emprint™ for HCC under 3cm

Kai Li (China)

LS6

Sponsored by AbbVie GK

Room 2 (Main Room B) 12:00-13:00 on October 17 (Sunday) 2021

Chair: Naoya Kato (Japan)

LS6-1 : HCV treatment with DAA changes the picture of HCC patients

Hideo Yoshida (Japan)

LS6-2 : Carcinogenesis after hepatitis C virus eradication

-Characteristics of genetic profile of hepatocarcinogenesis after SVR-

Shuntaro Obi (Japan)

LS7

Sponsored by Canon Medical Systems Corporation

Room 3 (Main Room A) 12:00-13:00 on October 17 (Sunday) 2021

Chair: Hitoshi Maruyama (Japan)

Clinical Experiences of Ultrasound in Ablation Therapy

LS7-1 : Aplio i-series / Prism Edition, See Ultrasound Imaging in a new light on Treatment

Yoshihiko Nomi (Japan)

LS7-2 : Real-world experiences in ablation therapies for hepatocellular carcinoma with Aplio i-series

Kaoru Tsuchiya (Japan)

Evening Seminar

ES1

Sponsored by Medtronic

Room 1 (Main Room C+D) 17:00-18:00 on October 15 (Friday) 2021

Chair: Zhang Boheng (China)

ES1-1 : Value of needle visualization in tumor ablation: case sharing

Somrach Thamtorawat (Thailand)

ES1-2 : Value of Emprint™ Ablation System

Shinichiro Nakamura (Japan)

ES2

Sponsored by Boston Scientific Japan K.K.

Room 2 (Main Room B) 17:00-18:00 on October 15 (Friday) 2021

Chair: Ryohei Kuwatsuru

The Power of Cryoablation

ES2-1 : The Point of View for Efficacy in Renal Cryoablation

Masaya Miyazaki (Japan)

Scientific Program

ES2-2 : The Point of View for Safety in Renal Cryoablation
Masashi Fujimori (Japan)

ES3

Sponsored by STARmed Co., Ltd.

Room 1 (Main Room C+D) 17:30-18:30 on October 16 (Saturday) 2021
Chair: Ryosuke Tateishi (Japan)

ES3-1 : Current Status of RFA and thermal ablation Advantages of multiple electrodes Single and
Multicenter study outcomes of No-Touch Ablation Technique Tips and Tricks
Jeong Min Lee (Korea)

ES4

Sponsored by Otsuka Pharmaceutical Co., Ltd.

Room 2 (Main Room B) 17:30-18:00 on October 16 (Saturday) 2021
Chair: Hitoshi Maruyama (Japan)

ES4-1 : New insights: the role of hepatic lipid metabolism in NASH and sarcopenia
Kazuyoshi Kon (Japan)